No­vo dumps pro­posed Ry­bel­sus suc­ces­sor for new­er mod­el

Bare­ly over a month af­ter gain­ing FDA ap­proval for the first GLP-1 drug Ry­bel­sus, No­vo Nordisk is dump­ing the com­pound it had been de­vel­op­ing as the lead suc­ces­sor to the Type 2 di­a­betes drug.

No­vo re­port­ed in their Q3 fi­nan­cials that they were dump­ing the next-gen­er­a­tion of oral semaglu­tide OG2023SC in fa­vor of what it’s call­ing “en­hanced next-gen­er­a­tion” ver­sions. The Dan­ish drug­mak­er had just wrapped up a first in-hu­man clin­i­cal tri­al for OG2023SC in Jan­u­ary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER